Meridian's IDkit:Hp, a Helicobacter pylori diagnostic test, receives FDA approval and expands its market reach.
The Technological Value of a Unique Non-Invasive Diagnostic Platform
Meridian Bioscience Israel's 'IDkit:Hp™' is a diagnostic solution that non-invasively detects Helicobacter pylori. This kit consists of 13C-urea tablets and Citrica citric acid powder. When ingested by the patient, it measures the activity of Helicobacter pylori, which breaks down urea in the stomach into carbon dioxide. When combined with the BreathID® Hp system, an analytical device, it analyzes the ratio of carbon dioxide isotopes (13CO2/12CO2 Ratio) in real-time in just 10-15 minutes. This is considered a technology that significantly improves patient convenience and clinical accuracy compared to endoscopic biopsy or stool antigen tests.
Overcoming Global Regulatory Barriers and Securing Reliability through FDA Approval
This diagnostic drug received New Drug Application (NDA 021314) approval from the U.S. Food and Drug Administration (FDA) on December 17, 2002, establishing long-term market credibility. In particular, it has secured indications for initial diagnosis and post-treatment monitoring in both pediatric patients (ages 3-17) and adults, making it highly scalable. As a combination medical product that integrates drugs and equipment, the FDA's stringent drug approval process acts as a regulatory barrier, preventing competitors from entering the market. In the healthcare industry, where regulatory compliance determines corporate survival, this approval is a key asset that solidifies Meridian's position in the global diagnostics market.
SD Biosensor's M&A Synergy and Strengthened Global Distribution Network
Meridian Bioscience was fully acquired by a consortium of SD Biosensor (137310) and SJL Partners for approximately $1.53 billion in cash on January 2023. This major deal was a strategic move by SD Biosensor to immediately secure a strong distribution network in the North American market and an FDA-approved product portfolio. The combination of Meridian's Israeli R&D capabilities and SD Biosensor's large-scale manufacturing capabilities has secured strong cost competitiveness and stable product supply in the point-of-care testing (POCT) market.
Growth and Competitive Landscape of the Helicobacter pylori Diagnostic Market
The global Helicobacter pylori diagnostic market is estimated at approximately $517 million to $700 million in 2024-2025 and is projected to grow at a compound annual growth rate (CAGR) of 4.6% to 7.9% by the mid-2030s. The main drivers of market growth are the increasing need for early diagnosis of Helicobacter pylori, which is identified as a risk factor for gastric cancer, and the spread of the 'test-and-treat' guideline for confirming eradication after treatment. While competitors such as Kibion's Heliprobe® and Shenzhen Zhonghe Headway's analytical system exist, Meridian's BreathID system, which features real-time molecular correlation spectroscopy (MCS) technology, is expanding its market share by leveraging its superior efficiency.
Meridian's 'IDkit:Hp' is an FDA-approved drug (NDA 021314) and a key reagent for the BreathID® system, a molecular diagnostic device, and serves as a benchmark for establishing the clinical reliability of non-invasive urea breath tests (UBT) in the Helicobacter pylori diagnostic market. In January 2023, SD Biosensor acquired Meridian for $1.53 billion, making this product a key lever for the Korean diagnostics company to immediately enter the North American distribution network and gain a cost advantage over competitors such as Kibion through large-scale production. The non-invasive testing paradigm shift in the Helicobacter pylori diagnostic market, which is expected to grow at a compound annual growth rate of 4 percent to 7 percent and reach up to $4.6 billion by the mid-2030s, will promote the introduction of new point-of-care (POCT) platforms. In the long term, it is expected to play a strategic role in increasing the success rate of new pipeline approvals by the U.S. FDA by combining Meridian's R&D capabilities with the trend of mandatory widespread gastric cancer screening and the expansion of pediatric indications (ages 3-17) in the United States.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA021314